NCT00053495 - Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination | Biotech Hunter

Enrollment

353

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

June 30, 2003

Study Completion Date

November 30, 2003

Conditions

Smallpox

Interventions

BIOLOGICAL

Vaccinia virus: ACAM2000 smallpox vaccine

Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml

BIOLOGICAL

vaccinia virus (calf lymph): Dryvax

Group 5 dose: 1.0x10-8th PFU/ml

Trial Locations (4)

Orlando Clinical Research Center, Orlando

Bio-Kinetic Clinical Applications, Springfield

PRA International, Lenexa

Memorial Hospital of Rhode IslandDivision of Infectious Diseases, Pawtucket